- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01672736
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
September 12, 2018 updated by: University Health Network, Toronto
A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
This is a multi-center, open-label, non-randomized study.
Patients will receive ASP7487 (OSI-906) in combination with bortezomib and dexamethasone.
Phase 1 involves dose escalation of the combination, whereas Phase 2 involves the expansion of ASP7487 (OSI-906) combined with bortezomib and dexamethasone at the MTD to establish the ORR.
This trial will accrue patients with relapsed or relapsed/refractory MM - a disease state for which bortezomib is approved to treat by the FDA and Health Canada.
The combination of ASP7487 (OSI-906) with bortezomib is supported by pre-clinical work in MM in which the combination with an IGF1-R inhibitor enhances anti-tumor activity of bortezomib.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The Phase 1 portion of the study will determine the MTD and DLTs of bortezomib administered on days 1, 4, 8 and 11 of a 21-day cycle combined with ASP7487 (OSI-906) dosed twice daily orally continuously.
The combination of ASP7487 (OSI-906) with bortezomib has not previously been tested.
The active agent bortezomib will be used during Cycle 1 - 8 at the recommended treatment dose of 1.3 mg/m2 days 1, 4, 8 and 11 and Cycles 9+ on days 1, 8, 15 and 22 of a 5-week cycle and ASP7487 (OSI-906) will be dose escalated form 75 mg to 150mg utilizing 3+3 design
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H2Y9
- Queen Elizabeth II Health Sciences Center
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Hopital Maisonneuve-Rosemont
-
Montreal, Quebec, Canada, H3T 1E3
- Sir Mortimer B. Davis-Jewish General Hospital
-
-
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Males or females, age 18 years or older.
- Relapsed or relapse/refractory MM with at least 1 prior line of therapy for phase 1 and 1 to 5 prior lines of therapy for phase 2.
Patients with measurable disease defined as at least one of the following
- Serum M-protein ≥ 0.5 g/dl (≥ 5 g/l)
- Urine M-protein ≥ 200 mg/24 h
- Serum free light chains (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/l) and an abnormal serum free light chain ratio (< 0.26 or > 1.65)
- Biopsy proven plasmacytoma. Prior biopsy is acceptable.
- If the serum protein electrophoresis is unreliable for routine M-protein measurement, quantitative immunoglobulin levels on nephrolometry or turbidometry will be followed.
- ECOG ≤ 2 OR Karnofsky ≥ 60%.
- Predose mean QTc≤ 450 msec or QTcF ≤ 450 msec.
- Negative pregnancy test for Females of childbearing potential.
- Voluntary, written informed consent.
- Ability to understand the purpose and risks of the study.
- Must be able to take and retain oral medications.
Inclusion Clinical Laboratories Criteria
- Absolute neutrophil count (ANC) > 1,000 cells/dL (1.0 x 109/L)
- Platelet count > 50,000 cells/dL (50 x 109/L)
- Hemoglobin ≥ 8.0 g/dL (4.96 mmol/L)
- Serum AST or ALT ≤ 1.2 x ULN
- Total bilirubin within normal limits
- Creatinine clearance ≥ 30 mL/min
- Serum creatinine ≤ 1.5 x ULN
- Serum calcium (ionized or corrected for albumin) ≥ 2.0 mmol/L (8.0 mg/dL or 1.0 mmol/L ionized calcium) to ≤ 1.2 x ULN.
- Serum potassium, and magnesium within normal limits
- HgbA1c of ≤ 7%
- Troponin I or T within normal limits
- BNP or NT-proBNP within normal limits
- Fasting glucose of ≤126 mg/dL (7.0 mmol/L).
- Resolution of prior treatment associated toxicities to ≤ grade 1
Exclusion Criteria
- Bortezomib refractory patients are not permitted on the Phase 2 part of the study.
- Diagnosed or treated for another malignancy within 3 years of enrollment, except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
- Patient has received other investigational drugs or chemotherapy within 21 days or approved anti-myeloma therapy within 14 days.
- History (within the last 6 months) of significant cardiovascular disease.
- Mean QTcF interval > 450 msec at screening.
- Prior autologous, peripheral stem cell transplant within 12 weeks of the first dose of study drug.
- Daily requirement for corticosteroids (except for inhalation corticosteroids).
- Patients with evidence of mucosal or internal bleeding and/or platelet transfusion refractory (i.e., unable to maintain a platelet count ≥ 50,000 cells/dL).
- Known active infection requiring parenteral or oral anti-infective treatment.
- Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation.
- Use of any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient.
- Patient has hypersensitivity to any of the components of study drugs.
- Known HIV or active hepatitis B or C viral infection.
- Diabetes mellitus currently requiring insulin or insulinotropic therapy or prior history of steroid induced diabetes.
- History of cerebrovascular accident (CVA) within 6 months prior to registration or that is not stable.
- Prior therapy with an IGF-1R inhibitor.
- Use of drugs that have a risk of causing QT interval prolongation and/or have a known risk of causing Torsades de Pointes (TdP) before 14 days or the recommended 5 half-life.
- Use of strong/moderate CYP1A2 inhibitors.
- Gastro-intestinal abnormalities that could affect the absorption of study drug.
- Peripheral neuropathy ≥ grade 2.
- Significant liver disease or metastatic disease to the liver
- History of amyloid, plasma cell leukemia or CNS involvement.
- Radiation therapy or major surgical procedure within 4 weeks of the first dose.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASP7487, Velcade, Dexamethasone
ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle.
Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles.
Dexamethasone is administered on bortezomib administration days at 20 mg
|
ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose of the Combination of ASP7487 (OSI-906) With Velcade and Dexamethasone
Time Frame: 45 months
|
|
45 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Suzanne Trudel, MD, UHN-PMH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Actual)
March 27, 2017
Study Completion (Actual)
December 27, 2017
Study Registration Dates
First Submitted
August 1, 2012
First Submitted That Met QC Criteria
August 22, 2012
First Posted (Estimate)
August 27, 2012
Study Record Updates
Last Update Posted (Actual)
September 13, 2018
Last Update Submitted That Met QC Criteria
September 12, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Bortezomib
Other Study ID Numbers
- PMHOSI906-MM001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on ASP7487, Velcade, Dexamethasone
-
University of OxfordAstellas Pharma Inc; European Organisation for Research and Treatment of Cancer... and other collaboratorsCompletedRefractory Ewing Sarcoma | Relapsed Ewing SarcomaUnited Kingdom, Germany, Netherlands, Italy, France
-
Centocor, Inc.WithdrawnMultiple MyelomaCanada, United States, Belgium, Poland, Bulgaria, Turkey, Ukraine, Australia, Korea, Republic of, New Zealand, Czech Republic, United Kingdom, Netherlands, India
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Laryngeal Cancer | Oral Cancer | Carcinoma, Squamous | Pharyngeal CancerUnited States
-
Intergroupe Francophone du MyelomeUnknown
-
University of LeedsMerck Sharp & Dohme LLC; Myeloma UKCompletedMultiple MyelomaUnited Kingdom
-
Intergroupe Francophone du MyelomeCompleted
-
PETHEMA FoundationCompleted
-
European Myeloma NetworkJanssen Research & Development, LLCActive, not recruitingMultiple MyelomaNorway, Denmark, Netherlands, Czechia, Australia, Turkey, Spain, Belgium, Switzerland, France, Greece, Italy, Poland
-
Janssen Research & Development, LLCCompletedMultiple MyelomaUnited States, Australia, Poland, Ukraine, Germany, Spain, Turkey, Korea, Republic of, Brazil, Russian Federation, Netherlands, Hungary, Sweden, Czechia, Mexico
-
University of ArkansasMillennium Pharmaceuticals, Inc.TerminatedMultiple MyelomaUnited States